Core Insights - Shares of Rezolute (RZLT) increased by 12.1% following a productive Type B meeting with the FDA regarding the phase III safety and efficacy study (sunRIZE) of ersodetug for congenital hyperinsulinism (HI) treatment [1][6] Study Overview - The sunRIZE study evaluated ersodetug in HI patients aged three months to 45 years who continued to experience hypoglycemia despite standard care, testing two dose levels (5 and 10 mg/kg) against a placebo in 63 patients over a six-month pivotal period [2] - The study failed to meet its primary endpoint, which assessed changes in average weekly hypoglycemia events based on self-monitored blood glucose (SMBG), with reductions not statistically significant compared to placebo [3] - The key secondary endpoint, evaluating average daily time spent in hypoglycemia via continuous glucose monitoring (CGM), also did not achieve nominal statistical significance at the pre-specified week 24 analysis [4] Stock Performance - Over the past six months, Rezolute's shares have declined by 71.2%, contrasting with the industry's growth of 13.5% [5] FDA Meeting Insights - During the FDA meeting, Rezolute discussed factors influencing the study's primary endpoint outcome, including behavioral dynamics and the limitations of SMBG in a heterogeneous patient population [7] - The FDA acknowledged the complexities in measuring hypoglycemia in congenital HI and the potential behavioral influences on study results [8] - The agency emphasized that approval decisions require substantial evidence from well-controlled studies, with discussions on CGM-based outcomes and preliminary open-label extension (OLE) data [9] Next Steps - The FDA encouraged Rezolute to submit full study reports and datasets for independent review, which will determine if the current data supports a potential marketing application for ersodetug [11] - Rezolute plans to provide an update on the program in the second half of 2026, expressing cautious optimism following the regulatory dialogue [11] Additional Developments - Beyond HI, Rezolute is advancing ersodetug in a phase III registrational study for tumor-induced HI, addressing a significant unmet medical need [12]

Core Insights - Rezolute provided updates on its Phase 3 sunRIZE trial for ersodetug, focusing on congenital hyperinsulinism treatment, following a meeting with the FDA on March 17 [1] Efficacy and Regulatory Insights - The primary endpoint of the sunRIZE trial was not statistically significant, but there were clinically meaningful improvements in hypoglycemia events as measured by continuous glucose monitoring [2] - The FDA highlighted the importance of well-controlled studies due to challenges posed by behavioral factors in clinical trials [2] - Rezolute is expected to submit further study reports for independent evaluation, which may lead to a marketing application for ersodetug later this year [3][4] Future Steps and Expectations - The FDA encouraged Rezolute to submit study reports and analysis datasets for independent evaluation, which will determine if sufficient evidence exists to support a marketing application for sunRIZE [4][5] - An update on the program is anticipated in the second half of 2026 [5] Technical Analysis - The stock is trading 13.9% below its 20-day simple moving average (SMA) and 48.5% below its 100-day SMA, indicating a bearish trend [6] - Shares have decreased by 15.84% over the past 12 months and are closer to their 52-week lows [6] - The RSI is at 35.46, indicating neutral territory, while the MACD shows bearish pressure with a value of -0.2377 [6][7] Analyst Consensus - The stock carries a Buy Rating with an average price target of $10.67, with recent analyst actions indicating mixed sentiments [8] - Rezolute shares were up 7.29% at $2.58 at the time of publication [8] - Key resistance is at $3.00 and key support is at $2.00, with various analysts adjusting their price targets [8]

Core Viewpoint - The FDA has encouraged Rezolute, Inc. to submit comprehensive data from the sunRIZE study and the ongoing open-label extension to inform the next steps for the program regarding the treatment of congenital hyperinsulinism with ersodetug [1][9]. Group 1: Study Outcomes - The sunRIZE study demonstrated reductions in hypoglycemia events from baseline, but did not meet its primary endpoint due to lack of statistical significance compared to placebo, which the company attributes to a pronounced study effect [2]. - Consistent and clinically significant improvements in time in hypoglycemia were observed via continuous glucose monitoring (CGM), although nominal statistical significance was not achieved at the pre-specified Week 24 end-of-treatment period [3]. - Summary results presented to the FDA included evidence of pharmacologic activity, consistent improvements in CGM-based glycemic endpoints, and preliminary favorable observations from the ongoing open-label extension [4]. Group 2: FDA Interaction - The FDA acknowledged the challenges posed by behavioral factors affecting clinical trials in this heterogeneous patient population and the limitations of self-monitored blood glucose metrics in measuring hypoglycemia [5][6]. - The agency reiterated the expectation for adequate and well-controlled studies as the standard for evaluating substantial evidence of efficacy for new therapies [7]. - The FDA expressed interest in the outcomes from the pivotal portion of the sunRIZE trial and plans to review the submitted study reports and analysis datasets for independent evaluation [9]. Group 3: Company Statements - The CEO of Rezolute expressed encouragement from the FDA meeting, noting that the agency did not dismiss the sunRIZE study outright despite not meeting its primary endpoint [10]. - The CEO of Congenital Hyperinsulinism International highlighted the importance of the open dialogue between the FDA and Rezolute, reflecting progress toward new treatment options for patients [11]. - Rezolute is focused on making ersodetug available to patients and families in need, emphasizing the commitment to advance meaningful improvements in care [11]. Group 4: Product Information - Ersodetug is a fully human monoclonal antibody designed to decrease receptor over-activation by insulin and related substances, potentially treating hypoglycemia due to any form of hyperinsulinism [12]. - Rezolute is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, with ersodetug being studied in clinical trials for both congenital and tumor-related HI [13].

Financial Data and Key Metrics Changes - In 2025, XOMA Royalty reported total GAAP income and revenue of $52.1 million, a significant increase from $28.5 million in 2024 [21] - Total cash receipts grew by 9% to $50.5 million, with royalty receipts reaching approximately $34 million, marking a 68% increase compared to 2024 [21] - Full-year GAAP net income was $31.7 million, compared to a GAAP net loss of $13.8 million in 2024 [23] Business Line Data and Key Metrics Changes - The company added 22 assets to its portfolio in 2025, including five in phase II or phase III trials, with a total cash outlay of only $25 million upfront [14] - Royalty receipts came from four programs in 2025, two more than in 2024, and six programs achieved clinical, regulatory, and business development events, leading to approximately $17 million in cash milestone payments [21] Market Data and Key Metrics Changes - The portfolio has expanded significantly, doubling the number of assets in active development from roughly 60 in 2023 to over 120 in 2025 [12] - The company has established a diverse and growing source of recurring receipts, with seven commercially available programs [5] Company Strategy and Development Direction - XOMA Royalty aims to build a diversified portfolio of biotechnology royalty and milestone assets while maintaining disciplined capital allocation [11] - The company is focused on innovative transactions and underappreciated opportunities, positioning itself as a unique source of capital for biotech innovation [20] - The strategy includes a balance between returning capital to shareholders and investing in new portfolio assets to increase breadth [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth prospects for royalty receipts, particularly from VABYSMO, OJEMDA, and MIPLYFFA, which are expected to ramp up significantly [32] - The company is approaching an inflection point where royalty receipts alone could cover operating expenses by 2027 [28] - Management remains optimistic about the potential for future milestone payments and royalty growth from a robust late-stage pipeline [9] Other Important Information - The company maintained a lean operating structure, achieving positive cash flow from operations and returning $16 million of capital through share buybacks [5] - XOMA Royalty ended the year with approximately $83 million in unrestricted cash and cash equivalents, providing ample firepower for future investments [27] Q&A Session Summary Question: Growth prospects for royalty receipts on approved products - Management indicated strong growth prospects, particularly from VABYSMO, which had double-digit growth last year, and positive expectations for OJEMDA and MIPLYFFA [32] Question: Confidence in Tremfya economic opportunity - Management expressed confidence in the breach claim related to Tremfya, citing historical relationships and potential royalty rates [34] Question: Prioritization of capital deployment between share buybacks and new deals - Management emphasized a philosophy of reducing equity base to increase cash flow per share while balancing external opportunities [46] Question: Size of the opportunity for Rezolute's ersodetug program - Management estimated the combined opportunity for the two indications to be approaching $1 billion, with a favorable split between congenital and tumor hyperinsulinism [48]

CORPORATE PRESENTATION NASDAQ COMMON: XOMA NASDAQ PERPETUAL PREFERRED SHARES: XOMAP, XOMAO THE ROYALTY AGGREGATOR FOR BIOTECH COMPANIES Q1 2026 DISCLAIMERS Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding: future potential monetization opportunities, active transactions with significant financial implications, collaborations poised for s ...

Summary of XOMA Corporation Conference Call Company Overview - **Company**: XOMA Corporation (NasdaqGM:XOMA) - **Industry**: Biotechnology - **Key Leadership**: CEO Owen Hughes, CFO Jeff Trigilio, Chief Investment Officer Brad Sitko Core Points and Arguments - **Portfolio Strategy**: XOMA aims to increase optionality within its portfolio, focusing on building a robust pipeline to withstand the binary nature of biotech. The company has 15 assets in phase 3 development, with 2 recent failures attributed to a higher-than-expected placebo effect. Despite this, the company's valuation remains stable, indicating confidence in its portfolio's potential [6][7]. - **Asset Growth**: Over the past three years, XOMA has added approximately 80 assets while reducing its share count, demonstrating effective capital management and a strategy to leverage future returns without diluting equity [8]. - **Tremfya Economics**: XOMA has a claim related to the commercialization of Tremfya, which it believes is integral to the drug's development. Although a recent arbitration was unsuccessful, the company sees potential in pursuing Johnson & Johnson for royalties, with a market cap of $450-$500 million and significant potential financial upside if successful [9][12][14]. - **Litigation Outlook**: The company is optimistic about the potential for a settlement or favorable ruling in its ongoing litigation, which could provide additional funding for business development and shareholder returns [19][22][27]. - **Takeda Transaction**: In 2025, XOMA completed a significant transaction with Takeda, exchanging one asset for nine additional assets, enhancing its portfolio and optionality. This deal is part of a broader strategy to diversify risk and increase net present value (NPV) [34][35]. Financial Highlights - **2025 Financial Performance**: XOMA reported over $50 million in top-line revenue, with $33 million from royalty receipts. The company achieved free cash flow positivity and repurchased $16 million of stock, indicating strong financial health [42][43]. - **Future Projections**: The company anticipates continued growth in royalties from approved therapies, with expectations of covering operational expenses and financial obligations through royalties alone by 2027. XOMA has over $620 million in net operating losses (NOLs) and capitalized R&D deductions, allowing it to maintain a low effective tax rate [51][52]. Upcoming Catalysts - **Clinical Trials**: XOMA has several upcoming catalysts, including the phase 2b readout for volixibat and a phase 3 trial for ersodetug, both of which could significantly impact the company's financials and market position [79][85]. - **Vabysmo Royalties**: Currently generating approximately $25 million annually from Vabysmo royalties, with expectations for continued growth. The drug's performance will influence the company's ability to pay off loans and return cash flows to shareholders [89][90]. Additional Insights - **Business Model**: XOMA's strategy focuses on acquiring non-dilutive capital and building a diversified portfolio to mitigate risks associated with biotech investments. The company emphasizes the importance of maintaining a flat share count while pursuing growth opportunities [60][64]. - **Market Positioning**: The company recognizes the challenges in biotech, including the unpredictability of clinical success and market dynamics. XOMA aims to leverage its unique assets and partnerships to create sustainable revenue streams [55][56]. This summary encapsulates the key points discussed during the conference call, highlighting XOMA's strategic direction, financial performance, and future opportunities within the biotechnology sector.

Core Viewpoint - Faruqi & Faruqi, LLP has initiated an investigation into Rezolute, Inc. following a significant drop in its stock price due to disappointing results from a clinical trial for its lead drug candidate, ersodetug [1]. Group 1: Company Overview - Rezolute, Inc. is a biopharmaceutical company focused on developing treatments for congenital hyperinsulinism [1]. - The company's lead drug candidate, ersodetug, was undergoing a Phase 3 clinical trial [1]. Group 2: Clinical Trial Results - The Phase 3 sunRIZE clinical trial for ersodetug failed to meet both its primary and key secondary endpoints [1]. - The highest dose in the trial showed reductions in hypoglycemia events that were not statistically significant compared to placebo [1]. Group 3: Stock Performance - On December 11, 2025, Rezolute's shares plummeted from approximately $10.94 to an intraday low of around $0.90, marking an approximate 85-90% decline [1]. - Trading was halted under Nasdaq's volatility controls due to the drastic drop in stock price [1].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rezolute, Inc. following a significant drop in its stock price due to disappointing clinical trial results for its lead drug candidate, ersodetug [1] Company Overview - Rezolute, Inc. is a biopharmaceutical company focused on developing treatments for congenital hyperinsulinism [1] - The company's lead drug candidate is ersodetug, which recently underwent a Phase 3 clinical trial [1] Clinical Trial Results - The Phase 3 sunRIZE clinical trial for ersodetug failed to meet both its primary and key secondary endpoints [1] - The highest dose of the drug showed reductions in hypoglycemia events that were not statistically significant compared to placebo [1] Stock Performance - Following the trial results, Rezolute's stock (RZLT) experienced a dramatic decline, dropping from approximately $10.94 to an intraday low of around $0.90, representing an approximate 85-90% decrease [1] - Trading was halted under Nasdaq's volatility controls due to the sharp decline [1]

Company Overview - Rezolute, Inc. is a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI) [3] - The company's antibody therapy, ersodetug, is designed to treat all forms of HI and has been studied in clinical trials and real-world cases for both congenital and tumor HI [3] Upcoming Events - Management will participate in the Citizens Life Sciences Conference on March 10-11, 2026, in Miami, FL [1] - One-on-one investor meetings will be held throughout the conference, and interested investors can contact their Citizens representative to schedule a meeting [2]

Core Viewpoint - Rezolute, Inc. has faced significant stock price decline following disappointing results from its Phase 3 clinical trial for its lead drug candidate, ersodetug, which did not meet primary and key secondary endpoints [5][6]. Group 1: Company Overview - Rezolute, Inc. is publicly traded on NASDAQ under the ticker RZLT [4]. - The company is focused on developing treatments for congenital hyperinsulinism [5]. Group 2: Clinical Trial Results - The Phase 3 sunRIZE clinical trial for ersodetug reported that the highest dose did not show statistically significant reductions in hypoglycemia events compared to placebo [5]. - The trial's failure to meet both primary and key secondary endpoints has led to investor disappointment [5]. Group 3: Stock Performance - On December 11, 2025, Rezolute's stock price plummeted from approximately $10.94 to an intraday low of around $0.90, marking an approximate 85-90% drop [6]. - Trading was halted under Nasdaq's volatility controls due to the drastic decline in stock price [6].